Blueprint Medicines Operating Income

Blueprint Medicines (BPMC) currently reports a operating income of $-170M as of March 2025. That compares with $-440M in the prior-year period — up 60.5% year over year. Use the charts on this page to explore Blueprint Medicines's operating income history and peer comparisons.

Blueprint Medicines's operating income increased from $-440M to $-170M — a 60.5% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Blueprint Medicines reported $-170M in operating income as of March 2025. That compares with $-440M in the prior-year period — up 60.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-170M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Blueprint Medicines, and consider following BPMC for alerts when major investors trade the stock.

Blueprint Medicines is classified in the Healthcare sector. On operating income, it currently shows $-170M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BPMC with unrelated industries.